Compare medicines
Put up to three medicines side by side. Useful for alternatives in the same class, or for seeing how two very different treatments differ.
| Attribute | ||
|---|---|---|
| In short | Immunotherapy for many cancers — the world's top-selling medicine. | PD-1 immunotherapy, often combined with ipilimumab. |
| Body system | Cancer | Cancer |
| Drug class | Immune checkpoint inhibitors | Immune checkpoint inhibitors |
| Supply | Prescription onlyWHO essential medicine | Prescription only |
| Main uses | Melanoma, Non-small cell lung cancer, Kidney, bladder, head and neck cancers, Triple-negative breast cancer, Cervical and endometrial cancer | Melanoma, Lung cancer, Kidney cancer, Oesophageal and stomach cancer, Hodgkin lymphoma |
| How it works | Takes the brakes off your immune cells so they can find and kill cancer. | Releases a brake on immune cells so they attack cancer. |
| Starts working | — | — |
| Half-life | About 22 days | About 25 days |
| Typical adult dose | 200 mg every 3 weeks or 400 mg every 6 weeks IV. | 240 mg every 2 weeks or 480 mg every 4 weeks IV. |
| Forms | IV infusion, Subcutaneous injection | IV infusion, Subcutaneous injection |
| Common side effects | Tiredness, Rash and itch, Diarrhoea, Underactive thyroid | Tiredness, Rash, Diarrhoea, Thyroid problems |
| Serious side effects | Pneumonitis, Colitis, Hepatitis, Type 1 diabetes, Myocarditis, Adrenal or pituitary failure | Pneumonitis, Colitis, Hepatitis, Endocrine failure |
| Don't take if | — | — |
| Alcohol | — | — |
| Pregnancy | Usually avoidedContraception needed. | Usually avoidedContraception needed. |
| Breastfeeding | — | — |
| In use since | 2014 | 2014 |
| Brand names | United States: Keytruda, Keytruda QlexUnited Kingdom: KeytrudaIndia: Keytruda | United States: Opdivo, Opdivo QvantigUnited Kingdom: OpdivoIndia: Opdyta, Opdivo |
| Legal status | — | — |
| ATC code | L01FF02 | L01FF01 |
Taken together
No interaction between these medicines is recorded in the atlas.
Open in the interaction checker